FLT3
FLT3 is a critical receptor tyrosine kinase that serves as the "survival switch" for the cells that build our blood. While essential for maintaining a healthy pool of immune cells, its mutation—particularly the structural ITD variant—acts as a molecular short circuit that drives one of the most aggressive forms of acute myeloid leukemia (AML).
Key Takeaways
- •FLT3 is the master switch for the survival and expansion of blood-forming stem cells.
- •The ITD mutation is a molecular "brick on the gas pedal" that forces blood cells to divide uncontrollably.
- •About 30% of adult AML patients have a FLT3 mutation, defining a high-risk group that needs targeted therapy.
- •FLT3 status can change over time; a patient can be negative at diagnosis but positive at relapse.
- •Newer FLT3 inhibitors like Gilteritinib are highly selective and can overcome specific resistance mutations.
Basic Information
- Gene Symbol
- FLT3
- Full Name
- FMS Related Receptor Tyrosine Kinase 3
- Also Known As
- CD135FLK2STK1
- Location
- 13q12.2
- Protein Type
- Receptor Tyrosine Kinase
- Protein Family
- Class III RTK family
Related Isoforms
The canonical full-length receptor expressed on hematopoietic progenitors.
Key SNPs
Common TKD mutation in the activation loop; confers resistance to 1st generation inhibitors.
Activation loop mutation frequently found in AML; leads to ligand-independent signaling.
Deletion in the kinase domain associated with constitutive activation.
The gatekeeper mutation; a major mechanism of resistance to gilteritinib.
Mutation in the ATP-binding pocket conferring resistance to several TKIs.
Overview
FLT3 (FMS Related Receptor Tyrosine Kinase 3) is a receptor that sits on the surface of early hematopoietic (blood-forming) stem cells. Its primary job is to respond to the FLT3 Ligand, a signal that tells these young cells to stay alive and begin the process of becoming mature white blood cells. This signaling is essential for maintaining a robust immune system and a constant supply of fresh blood.
In the context of leukemia, FLT3 is one of the most significant oncogenes. Mutations in FLT3—especially the Internal Tandem Duplication (ITD)—break the receptors natural autoinhibitory "switch." This leaves the receptor permanently active, flooding the cell with survival signals that prevent natural cell death and drive the rapid accumulation of immature leukemic "blasts" in the bone marrow.
Conceptual Model
A simplified mental model for the pathway:
The ITD mutation acts like a "brick on the gas pedal," forcing the receptor to stay active without any external ligand.
Core Health Impacts
- • Stem Cell Survival: Essential for the survival of hematopoietic stem cell populations.
- • Cell Differentiation: Drives the early differentiation of myeloid and lymphoid lineages.
- • Oncogenic Driver: Primary oncogenic driver in roughly one-third of adult AML cases.
- • Immune Surveillance: Influences the development of dendritic cells and immune surveillance.
- • Prognostic Marker: Serves as a critical prognostic biomarker for leukemia risk stratification.
Protein Domains
Extracellular Region
Contains five immunoglobulin-like domains that facilitate FLT3 ligand binding.
Juxtamembrane (JM)
Normally acts as an autoinhibitory "switch." Site of ITD mutations.
Kinase Domain (TKD)
The catalytic engine; hotspot for point mutations (e.g., D835) that activate the enzyme.
Upstream Regulators
FLT3 Ligand (FL) Activator
The primary physiological ligand; promotes survival and proliferation of hematopoietic progenitors.
Internal Tandem Duplication Activator
Duplication of sequences in the juxtamembrane domain that breaks autoinhibition.
Kinase Domain Mutations Activator
Point mutations (mostly at D835) that lock the kinase domain in an active conformation.
AXL Receptor Crosstalk Modulator
AXL can heterodimerize with FLT3 or provide bypass signals in the context of TKI therapy.
Autocrine Signaling Activator
Some leukemic cells produce their own FLT3 ligand, creating a self-sustaining growth loop.
Downstream Targets
STAT5 Activates
Strongly activated by mutant FLT3 (especially ITD), driving aggressive survival programs.
PI3K / AKT Pathway Activates
Crucial for metabolic reprogramming and protection against apoptosis in leukemic blasts.
MAPK / ERK Pathway Activates
Drives cell cycle entry and proliferation in response to FLT3 signaling.
Pim-1 Kinase Activates
Upregulated by FLT3; stabilizes the receptor and promotes a pro-survival environment.
SOCS1 Inhibits
Part of the negative feedback loop that normally terminates FLT3 signals.
C/EBP-alpha Inhibits
Transcription factor whose activity is often suppressed by hyperactive FLT3, blocking myeloid differentiation.
Role in Aging
FLT3 signaling is a major factor in the age-related decline of the blood-forming system and the rising incidence of myeloid malignancies in older adults.
Stem Cell Aging
Declining FLT3 ligand levels or receptor sensitivity in the marrow can reduce the output of healthy lymphoid cells.
Somatic Evolution
The incidence of FLT3 mutations increases with age, reflecting the selection of fit clones in the aged marrow environment.
Myeloid Bias
Age-related shifts in FLT3 signaling favor the production of myeloid cells over lymphoid cells (immunosenescence).
Proteostasis Stress
Mutant FLT3 proteins (especially ITD) are often misfolded, triggering proteotoxic stress that cells must manage as they age.
Inflammatory Niche
Chronic RTK signaling in clones contributes to a pro-inflammatory marrow microenvironment.
Epigenetic Interplay
FLT3 mutations often co-occur with age-related mutations in epigenetic regulators like DNMT3A.
Disorders & Diseases
Acute Myeloid Leukemia (AML)
Mutations drive blast proliferation and are associated with a poor prognosis if not targeted aggressively.
Acute Lymphoblastic Leukemia
FLT3 is frequently overexpressed or mutated in MLL-rearranged infantile ALL.
Myelodysplastic Syndromes
Mutations in FLT3 can emerge during the progression of MDS to AML, signaling rapid growth.
Systemic Mastocytosis
FLT3 mutations are occasionally found and may contribute to disease severity.
Bone Marrow Failure
Disruption of the FLT3 axis is a factor in several marrow failure syndromes.
Interventions
Supplements
Essential for supporting patients during aggressive induction chemotherapy for AML.
Studied for their ability to support systemic health and modulate inflammatory pathways.
Important for immune function; low levels are frequently observed in patients with myeloid malignancies.
Lifestyle
Critical for AML patients due to the severe neutropenia caused by the disease and treatment.
Frequent testing is required to manage the complications of bone marrow failure.
Maintaining adequate nutrition and hydration during high-intensity TKI treatment.
Regular RBC and platelet transfusions are often necessary to manage anemia and bleeding.
Medicines
Potent 2nd generation inhibitor targeting both ITD and TKD mutations; used in relapsed AML.
Multi-kinase inhibitor; the first targeted therapy approved for newly diagnosed FLT3+ AML.
Highly selective 2nd generation inhibitor for FLT3-ITD; shows high potency.
Investigational type I inhibitor effective against both ITD and D835 resistance mutations.
Multi-kinase inhibitor sometimes used for its FLT3-inhibitory activity.
Lab Tests & Biomarkers
Genetic Status
Standard assay to detect ITD length and calculate the allelic ratio.
NGS or PCR screening for point mutations like D835 and F691L.
Using mutant FLT3 levels to track minimal residual disease after treatment.
Disease Burden
The percentage of immature leukemic cells in the marrow.
Measures the level of FLT3 protein on the surface of leukemic cells.
Non-specific marker of high tumor burden and rapid cell turnover.
Hormonal Interactions
Insulin / IGF-1 Growth Amplifier
Synergistic signaling with RTKs like FLT3 can promote leukemic cell survival.
Cortisol Immune Modulator
Glucocorticoids are often part of supportive care in AML treatment.
Growth Hormone Indirect Regulator
Influence on IGF-1 levels may modulate the background growth environment.
Thyroid Hormone Metabolic Modulator
Regulates the baseline metabolic rate of hematopoietic cells.
Deep Dive
Network Diagrams
FLT3-ITD Structural Logic
Mechanism of TKI Resistance
The ITD Mechanism: Unlocking the Autoinhibitory Switch
In wild-type FLT3, the juxtamembrane (JM) domain acts as a physical barrier that prevents the kinase domain from assuming its active shape. Dimerization by ligand normally moves this barrier aside.
- The ITD Disruption: The Internal Tandem Duplication (ITD) is an insertion of extra amino acids right into this JM switch. This structural change “unspools” the JM domain, permanently removing the barrier even in the absence of a ligand. The kinase is thus constitutively free to signal.
- Signal Divergence: FLT3-ITD signaling is not just stronger than wild-type signaling; it is different. The ITD mutant signals more intensely through the STAT5 pathway, while the wild-type receptor primarily uses Ras/MAPK and PI3K.
TKI Evolution: Type I vs. Type II Inhibitors
The treatment of FLT3+ AML is defined by the battle against kinase domain resistance.
- Type II Inhibitors (e.g., Quizartinib): These bind to the receptor when it is in the “inactive” (D-F-G out) conformation. They are highly selective for the ITD mutation but are often thwarted by point mutations in the activation loop (TKD mutations) that lock the receptor in the “active” state.
- Type I Inhibitors (e.g., Gilteritinib): These can bind to the receptor in its active state. This allows them to overcome both the ITD mutation and many of the TKD point mutations that cause resistance to Type II drugs.
- The Gatekeeper (F691L): This mutation sits at the back of the ATP pocket and causes high-level resistance to almost all current drugs by physically blocking their entry.
Clonal Evolution and Clinical Vigilance
One of the most important aspects of FLT3 biology is that it is often a “late” mutation in leukemia. A patient might start with a different mutation (like DNMT3A or NPM1) and only acquire the FLT3 mutation as the disease becomes more aggressive.
Because of this, FLT3 status can be “unstable.” A patient who is FLT3-negative at diagnosis can become FLT3-positive at relapse. This “clonal evolution” means that doctors must re-test the bone marrow every time the leukemia returns to ensure the most effective targeted therapies are being used.
Interpreting FLT3 Status
The Allelic Ratio (AR): It is not just "ITD+" or "ITD-." A high AR (>0.5) is a major driver for choosing a stem cell transplant.
Clonal Evolution: FLT3 status is unstable. A patient can be negative at diagnosis but become positive at relapse.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Early study establishing the high frequency of FLT3 expression in AML.
First description of the ITD mutation and its functional impact on FLT3 activation.
The RATIFY trial establishing the first targeted standard of care for FLT3+ AML.
The ADMIRAL trial demonstrating superior survival with gilteritinib in the relapsed setting.
Identified the D835 activation loop mutation as a recurrent driver in AML.
Authoritative review on the biology and clinical management of FLT3 mutations.